Global Continuous Subcutaneous Insulin Infusion Market Size Study by Product, Patient Type, End-Use, and Regional Forecasts 2022-2032

Description

The Global Continuous Subcutaneous Insulin Infusion Market, valued at approximately USD 0.69 billion in 2023, is poised to grow exponentially, reaching an estimated USD 1.34 billion by 2032, with a compelling CAGR of 9.00% over the forecast period 2024-2032. This growth is primarily attributed to the increasing prevalence of diabetes worldwide, combined with the rising demand for advanced insulin delivery systems that improve glycemic control and enhance patient compliance. The transition toward minimally invasive technologies has underscored the importance of continuous subcutaneous insulin infusion (CSII) systems, which offer precision and adaptability in diabetes management.

CSII systems, encompassing patch pumps and tethered pumps, are revolutionizing the landscape of diabetes care by delivering basal and bolus insulin doses in a controlled manner. Their ability to minimize the challenges associated with traditional insulin therapy methods has significantly enhanced their adoption. Furthermore, technological advancements, such as integration with continuous glucose monitoring (CGM) systems and smartphone connectivity, have positioned these devices as indispensable tools for personalized diabetes management. However, challenges such as high costs and limited access in emerging economies remain pressing concerns, which stakeholders are addressing through strategic pricing models and educational initiatives.

The market's growth trajectory is further bolstered by favorable healthcare policies and increased investments in research and development activities. The rising prevalence of diabetes Type 1, particularly in pediatric and young adult populations, has fueled the demand for user-friendly and compact insulin infusion solutions. Additionally, expanding awareness campaigns emphasizing early diagnosis and effective diabetes management are creating robust growth opportunities across various regions.

Regionally, North America dominates the Continuous Subcutaneous Insulin Infusion Market, underpinned by a strong healthcare infrastructure, high adoption rates of innovative technologies, and a significant patient pool. Europe follows suit, driven by government initiatives promoting diabetes management and the presence of leading market players. Meanwhile, the Asia Pacific region is expected to witness the fastest growth during the forecast period, attributed to the rising incidence of diabetes, increasing healthcare spending, and growing awareness regarding advanced insulin delivery systems. Latin America and the Middle East & Africa also present promising potential, supported by improving healthcare facilities and heightened focus on diabetes care.

Major market players included in this report are:

Medtronic plc
Tandem Diabetes Care, Inc.
Insulet Corporation
Roche Diabetes Care
Ypsomed Holding AG
Sooil Development Co., Ltd.
Cellnovo Group SA
Eli Lilly and Company
Novo Nordisk A/S
Animas Corporation (Johnson & Johnson)
Beta Bionics, Inc.
Valeritas Holdings, Inc.
Debiotech SA
Senseonics Holdings, Inc.
Sanofi

The detailed segments and sub-segment of the market are explained below:

By Product:

Patch Pumps
Tethered Pumps

By Patient Type:

Diabetes Type 1
Diabetes Type 2

By End-Use:

Hospitals
Clinics
Homecare Settings

By Region:

North America:

U.S.
Canada

Europe:

UK
Germany
France
Spain
Italy
Rest of Europe

Asia Pacific:

China
India
Japan
Australia
South Korea
Rest of Asia Pacific

Latin America:

Brazil
Mexico
Rest of Latin America

Middle East & Africa:

Saudi Arabia
South Africa
Rest of Middle East & Africa

Years considered for the study are as follows:

Historical Year: 2022
Base Year: 2023
Forecast Period: 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional-level analysis for each market segment.
Detailed analysis of geographical landscape with country-level insights across major regions.
Competitive landscape featuring information on major players and their strategies.
Analysis of key business strategies and recommendations for future market approaches.
Comprehensive analysis of the competitive structure of the market.
Demand-side and supply-side analysis of the market.

Chapter 1. Global Continuous Subcutaneous Insulin Infusion Market Executive Summary

1.1. Global Continuous Subcutaneous Insulin Infusion Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Product
- 1.3.2. By Patient Type
- 1.3.3. By End-Use
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Continuous Subcutaneous Insulin Infusion Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory Frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Continuous Subcutaneous Insulin Infusion Market Dynamics

3.1. Market Drivers
- 3.1.1. Increasing Prevalence of Diabetes Worldwide
- 3.1.2. Rising Demand for Advanced Insulin Delivery Systems
- 3.1.3. Technological Advancements in Insulin Infusion Devices
3.2. Market Challenges
- 3.2.1. High Costs of Continuous Subcutaneous Insulin Infusion Systems
- 3.2.2. Limited Access in Emerging Economies
3.3. Market Opportunities
- 3.3.1. Expansion into Emerging Markets
- 3.3.2. Innovations in Device Integration and Connectivity
- 3.3.3. Strategic Collaborations and Partnerships

Chapter 4. Global Continuous Subcutaneous Insulin Infusion Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Continuous Subcutaneous Insulin Infusion Market Size & Forecasts by Product 2022-2032

5.1. Segment Dashboard
5.2. Global Continuous Subcutaneous Insulin Infusion Market: Product Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 5.2.1. Patch Pumps
- 5.2.2. Tethered Pumps

Chapter 6. Global Continuous Subcutaneous Insulin Infusion Market Size & Forecasts by Patient Type 2022-2032

6.1. Segment Dashboard
6.2. Global Continuous Subcutaneous Insulin Infusion Market: Patient Type Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 6.2.1. Diabetes Type 1
- 6.2.2. Diabetes Type 2

Chapter 7. Global Continuous Subcutaneous Insulin Infusion Market Size & Forecasts by End-Use 2022-2032

7.1. End-Use
- 7.1.1. Hospitals
- 7.1.2. Clinics
- 7.1.3. Homecare Settings

Chapter 8. Global Continuous Subcutaneous Insulin Infusion Market Size & Forecasts by Region 2022-2032

8.1. North America Continuous Subcutaneous Insulin Infusion Market
- 8.1.1. U.S. Continuous Subcutaneous Insulin Infusion Market
  - 8.1.1.1. End Use Breakdown Size & Forecasts, 2022-2032
  - 8.1.1.2. Product Breakdown Size & Forecasts, 2022-2032
- 8.1.2. Canada Continuous Subcutaneous Insulin Infusion Market
8.2. Europe Continuous Subcutaneous Insulin Infusion Market
- 8.2.1. UK Continuous Subcutaneous Insulin Infusion Market
- 8.2.2. Germany Continuous Subcutaneous Insulin Infusion Market
- 8.2.3. France Continuous Subcutaneous Insulin Infusion Market
- 8.2.4. Spain Continuous Subcutaneous Insulin Infusion Market
- 8.2.5. Italy Continuous Subcutaneous Insulin Infusion Market
- 8.2.6. Rest of Europe Continuous Subcutaneous Insulin Infusion Market
8.3. Asia Pacific Continuous Subcutaneous Insulin Infusion Market
- 8.3.1. China Continuous Subcutaneous Insulin Infusion Market
- 8.3.2. India Continuous Subcutaneous Insulin Infusion Market
- 8.3.3. Japan Continuous Subcutaneous Insulin Infusion Market
- 8.3.4. Australia Continuous Subcutaneous Insulin Infusion Market
- 8.3.5. South Korea Continuous Subcutaneous Insulin Infusion Market
- 8.3.6. Rest of Asia Pacific Continuous Subcutaneous Insulin Infusion Market
8.4. Latin America Continuous Subcutaneous Insulin Infusion Market
- 8.4.1. Brazil Continuous Subcutaneous Insulin Infusion Market
- 8.4.2. Mexico Continuous Subcutaneous Insulin Infusion Market
- 8.4.3. Rest of Latin America Continuous Subcutaneous Insulin Infusion Market
8.5. Middle East & Africa Continuous Subcutaneous Insulin Infusion Market
- 8.5.1. Saudi Arabia Continuous Subcutaneous Insulin Infusion Market
- 8.5.2. South Africa Continuous Subcutaneous Insulin Infusion Market
- 8.5.3. Rest of Middle East & Africa Continuous Subcutaneous Insulin Infusion Market

Chapter 9. Competitive Intelligence

9.1. Key Company SWOT Analysis
- 9.1.1. Medtronic plc
- 9.1.2. Tandem Diabetes Care, Inc.
- 9.1.3. Insulet Corporation
9.2. Top Market Strategies
9.3. Company Profiles
- 9.3.1. Medtronic plc
  - 9.3.1.1. Key Information
  - 9.3.1.2. Overview
  - 9.3.1.3. Financial (Subject to Data Availability)
  - 9.3.1.4. Product Summary
  - 9.3.1.5. Market Strategies
- 9.3.2. Tandem Diabetes Care, Inc.
- 9.3.3. Insulet Corporation
- 9.3.4. Roche Diabetes Care
- 9.3.5. Ypsomed Holding AG
- 9.3.6. Sooil Development Co., Ltd.
- 9.3.7. Cellnovo Group SA
- 9.3.8. Eli Lilly and Company
- 9.3.9. Novo Nordisk A/S
- 9.3.10. Animas Corporation (Johnson & Johnson)
- 9.3.11. Beta Bionics, Inc.
- 9.3.12. Valeritas Holdings, Inc.
- 9.3.13. Debiotech SA
- 9.3.14. Senseonics Holdings, Inc.
- 9.3.15. Sanofi

Chapter 10. Research Process

10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
10.2. Research Attributes